Stephen Goodall has extensive experience in intellectual property, pharmaceutical development, manufacturing, regulatory strategy and clinical development. He also has extensive experience in the pre-clinical, IND, regulatory and human clinical phases of drug development.
Dr Goodall is the co-founder and chief operating officer of Firebrick Pharma, which is awaiting the approval of a nasal spray medicine that targets the cause of colds. Prior to that, he was the chief operating officer of Viralytics, which was later acquired in 2018 for $500 million by the US big pharma company, Merck. Dr Goodall was also the director of pharmaceutical development at Vapotronics, where he managed all aspects of inhaled drug development and formulation; and a director of development at AGEN Biomedical.
